Mitsui Chemicals’ ¥1.84 Trillion JSR Deal Sends Shares Down Nearly 13%
Key Facts
Mitsui Chemicals signed an agreement on November 9, 2026, to buy JSR shares from funds managed by JIC Capital, with the Development Bank of Japan participating; JSR will become a consolidated subsidiary once the deal is completed. Reuters valued the transaction at about ¥1.84 trillion, or $11.61 billion. The deal includes a planned ¥200 billion investment from the bank, making it a joint transaction between Mitsui and the bank. Mitsui says combining the two companies will strengthen its semiconductor materials business and information and communications technology solutions segment. Chief Executive Satoshi Ichimura described the deal as "not merely a reinforcement of our semiconductor materials business, but a strategic deal to accelerate the transformation of our portfolio."
Mitsui is targeting about ¥40 billion in additional annual profit from growth and cost synergies by fiscal 2035. The target is tied to expanding its chip materials and information and communications technology solutions businesses by combining the two companies’ operations. JSR said semiconductor demand remained firm in fiscal 2026 as investment related to artificial intelligence broadened. It added that generative AI applications supported demand for advanced chip materials and packaging services. The company also pointed to growth in advanced materials for logic chips and DRAM, and to the opening of new manufacturing and development sites in Taiwan during fiscal 2026.
The planned financing for the deal relies on a ¥1,640 billion bridge loan from Mitsui’s main financial institutions, alongside the Development Bank of Japan’s ¥200 billion investment. The company expects its net debt-to-EBITDA ratio to temporarily exceed four times after completion. It plans to refinance the bridge loan within a year of completing the acquisition through a mix of loans, bonds and equity. Its plan includes ¥300 billion in financing that rating agencies are expected to recognize as equity. The company has also set a cap of ¥150 billion on raising funds through common stock, including treasury shares.
Financing concerns weighed on the stock in the November 9 session, with Mitsui Chemicals shares falling about 13% to around ¥1,500, according to Reuters. The drop followed a decline of more than 10% in the previous week after the deal was first reported. The news agency linked investor concerns to the scale of financing required for the acquisition. Reuters ranked the deal among the sector’s largest, noting that it is more than double Showa Denko’s $4.55 billion acquisition of Hitachi Chemical in 2020. The comparison places the new deal within a wave of restructuring of chemical assets tied to the semiconductor industry.
Mitsui is targeting completion in the second half of the fiscal year ending in March 2028, subject to regulatory approvals in Japan and abroad and the fulfillment of other conditions. The company said the expected impact on its results for the fiscal year ending in March 2027 would be slight. Alongside the acquisition, JSR plans to continue treating its life sciences operations, including contract research, development and manufacturing services, as non-core businesses. The company intends to explore options for those businesses. The deal comes as Mitsui seeks to expand its presence in semiconductor materials, with financing and regulatory approvals remaining among its key execution considerations.